Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus placebo in primary or secondary progressive multiple sclerosis without relapse
2024-516672-16-00Phase 3Completed
- Sponsor
- AB Science
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) comparing Masitinib with Placebo (2 arms). Primary endpoint: Time to 12-week confirmed EDSS progression. Started Jan 2025; status: completed.
02
Drugs
masitinib
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-516672-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516672-16-00.